F Giugliano1,2, J Uliano1,2, V A A Zia3, D Trapani1, A Marra1,2, G Viale1, E Ferraro1,2, A Esposito1, C Criscitiello1,2, P D'amico1,2, G Curigliano4,5. 1. Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy. 2. Department of Oncology and Hematology (DIPO), University of Milan "La Statale", Via Festa Del Perdono 1, 20122, Milan, Italy. 3. Division of Medical Oncology, Escola Paulista de Medicina, Federal University of São Paulo (UNIFESP), São Paulo, SP, 04037-004, Brazil. 4. Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy. Giuseppe.curigliano@ieo.it. 5. Department of Oncology and Hematology (DIPO), University of Milan "La Statale", Via Festa Del Perdono 1, 20122, Milan, Italy. Giuseppe.curigliano@ieo.it.
Abstract
PURPOSE: Breast cancer (BC) is a leading cause of morbidity, disability, and mortality in women, worldwide; triple-negative BC (TNBC) is a subtype traditionally associated with poorer prognosis. TNBC special histology subtypes present distinct clinical and molecular features and sensitivity to antineoplastic treatments. However, no consensus has been defined on the best adjuvant therapy. The aim of the review is to study the evidence from literature to inform the choice of adjuvant treatments in this setting. METHODS: We systematically searched literature assessing the benefit of adjuvant chemotherapy in patients with TNBC special histotypes (PROSPERO: CRD42020153818). RESULTS: We screened 6404 records (15 included). All the studies estimated the benefit of different chemotherapy regimens, in retrospective cohorts (median size: 69 patients (range min-max: 17-5142); median follow-up: 51 months (range: 21-268); mostly in Europe and USA). In patients with early-stage adenoid cystic TNBC, a marginal role of chemotherapy was reported. Similar for apocrine TNBC. Medullary tumors exhibited an intrinsic good prognosis with a limited role of chemotherapy, suggested to be modulated by the presence of tumor-infiltrating lymphocytes. A significant impact of chemotherapy on the overall survival was estimated in patients with metaplastic TNBC. Limitations were related to the retrospective design of all the studies and heterogeneous treatments received by the patients. CONCLUSIONS: There is potential opportunity to consider treatment de-escalation and less intense therapies in some patients with early, special histology-type TNBC. International efforts are indispensable to validate prospective clinical decision models.
PURPOSE:Breast cancer (BC) is a leading cause of morbidity, disability, and mortality in women, worldwide; triple-negative BC (TNBC) is a subtype traditionally associated with poorer prognosis. TNBC special histology subtypes present distinct clinical and molecular features and sensitivity to antineoplastic treatments. However, no consensus has been defined on the best adjuvant therapy. The aim of the review is to study the evidence from literature to inform the choice of adjuvant treatments in this setting. METHODS: We systematically searched literature assessing the benefit of adjuvant chemotherapy in patients with TNBC special histotypes (PROSPERO: CRD42020153818). RESULTS: We screened 6404 records (15 included). All the studies estimated the benefit of different chemotherapy regimens, in retrospective cohorts (median size: 69 patients (range min-max: 17-5142); median follow-up: 51 months (range: 21-268); mostly in Europe and USA). In patients with early-stage adenoid cystic TNBC, a marginal role of chemotherapy was reported. Similar for apocrine TNBC. Medullary tumors exhibited an intrinsic good prognosis with a limited role of chemotherapy, suggested to be modulated by the presence of tumor-infiltrating lymphocytes. A significant impact of chemotherapy on the overall survival was estimated in patients with metaplastic TNBC. Limitations were related to the retrospective design of all the studies and heterogeneous treatments received by the patients. CONCLUSIONS: There is potential opportunity to consider treatment de-escalation and less intense therapies in some patients with early, special histology-type TNBC. International efforts are indispensable to validate prospective clinical decision models.
Entities:
Keywords:
Adjuvant treatment intensity customization; Escalation and de-escalation; Special histology; Triple-negative breast cancer; WHO classification
Authors: Felipe C Geyer; Fresia Pareja; Britta Weigelt; Emad Rakha; Ian O Ellis; Stuart J Schnitt; Jorge S Reis-Filho Journal: Am J Pathol Date: 2017-07-20 Impact factor: 4.307
Authors: H J Burstein; G Curigliano; S Loibl; P Dubsky; M Gnant; P Poortmans; M Colleoni; C Denkert; M Piccart-Gebhart; M Regan; H-J Senn; E P Winer; B Thurlimann Journal: Ann Oncol Date: 2019-10-01 Impact factor: 32.976
Authors: Matthew D Burstein; Anna Tsimelzon; Graham M Poage; Kyle R Covington; Alejandro Contreras; Suzanne A W Fuqua; Michelle I Savage; C Kent Osborne; Susan G Hilsenbeck; Jenny C Chang; Gordon B Mills; Ching C Lau; Powel H Brown Journal: Clin Cancer Res Date: 2014-09-10 Impact factor: 12.531
Authors: B Weigelt; H M Horlings; B Kreike; M M Hayes; M Hauptmann; L F A Wessels; D de Jong; M J Van de Vijver; L J Van't Veer; J L Peterse Journal: J Pathol Date: 2008-10 Impact factor: 7.996
Authors: Christopher J Schwartz; Edi Brogi; Antonio Marra; Arnaud F Da Cruz Paula; Gouri J Nanjangud; Edaise M da Silva; Sujata Patil; Shreena Shah; Katia Ventura; Pedram Razavi; Larry Norton; Timothy D'alfonso; Britta Weigelt; Fresia Pareja; Jorge S Reis-Filho; Hannah Y Wen Journal: Mod Pathol Date: 2021-10-01 Impact factor: 8.209
Authors: Juan Ji; Fang Zhang; Fanglei Duan; Hong Yang; Jun Hou; Yang Liu; Jie Dai; Qiong Liao; Xian Chen; Qingsong Liu Journal: Sci Rep Date: 2022-05-19 Impact factor: 4.996